We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

89 hedge funds and large institutions have $364M invested in KalVista Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 28 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more capital invested

Capital invested by funds: $314M → $364M (+$49.2M)

11% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 28

1.96% more ownership

Funds ownership: 97.2% → 99.16% (+2%)

8% less funds holding

Funds holding: 97 → 89 (-8)

42% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 19

Holders
89
Holders Change
-8
Holders Change %
-8.25%
% of All Funds
1.4%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
11
Increased
31
Reduced
28
Closed
19
Calls
$1.66M
Puts
–
Net Calls
+$1.66M
Net Calls Change
+$1.64M

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$9.31M
2
GPP
Great Point Partners
Connecticut
+$6.64M
3
WP
Woodline Partners
California
+$5.15M
4
DTC
Deep Track Capital
Connecticut
+$3.3M
5
PM
Prosight Management
Texas
+$2.58M

Top Sellers

Rank Fund Capital Flow
1
FM
Frazier Management
Washington
-$17.3M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$6.68M
3
DM
Deerfield Management
New York
-$4.95M
4
SFM
Sphera Funds Management
Israel
-$4.18M
5
EAM
Eventide Asset Management
Massachusetts
-$1.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$2.46M +$967K +67,274 +68%
NFGH
27
Nan Fung Group Holdings
Hong Kong
$1.16M – – –
Dimensional Fund Advisors
28
Dimensional Fund Advisors
Texas
$1.11M -$1.33M -92,779 -55%
Bank of America
29
Bank of America
North Carolina
$1.03M +$39K +2,717 +4%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.03M +$55.1K +3,838 +6%
Morgan Stanley
31
Morgan Stanley
New York
$993K +$61.7K +4,295 +7%
N
32
Nuveen
North Carolina
$962K +$11.6K +805 +1%
Walleye Capital
33
Walleye Capital
New York
$946K +$923K +64,210 New
Citadel Advisors
34
Citadel Advisors
Florida
$928K +$655K +45,564 +262%
CL
35
CSS LLC
Illinois
$873K +$348K +24,200 +69%
Charles Schwab
36
Charles Schwab
California
$862K +$14.4K +1,000 +2%
Two Sigma Advisers
37
Two Sigma Advisers
New York
$821K -$853K -59,400 -52%
Rafferty Asset Management
38
Rafferty Asset Management
New York
$701K -$239K -16,637 -26%
AC
39
Apogem Capital
New York
$645K +$186K +12,967 +42%
UBS Group
40
UBS Group
Switzerland
$634K -$152K -10,570 -20%
PVI
41
Pura Vida Investments
New York
$610K +$4.4K +306 +0.7%
BC
42
Birchview Capital
Vermont
$590K – – –
IC
43
Ikarian Capital
Texas
$586K +$45.3K +3,154 +9%
Marshall Wace
44
Marshall Wace
United Kingdom
$536K +$522K +36,359 New
State of Wisconsin Investment Board
45
State of Wisconsin Investment Board
Wisconsin
$500K +$180K +12,500 +58%
First Trust Advisors
46
First Trust Advisors
Illinois
$470K -$26K -1,807 -5%
TRSOTSOK
47
Teachers Retirement System of the State of Kentucky
Kentucky
$447K +$58.9K +4,100 +16%
EW
48
Evoke Wealth
California
$377K – – –
AA
49
ALPS Advisors
Colorado
$372K -$43.9K -3,055 -11%
GCP
50
GSA Capital Partners
United Kingdom
$346K +$172K +12,003 +104%
1
2
3 4 5

KALV Hedge Fund Activity: Q1 2022 in Review

89 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2022, worth a combined $364M — up 16% from $314M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of KALV and 11 opened new positions — a net loss of 8 holders — while 28 trimmed existing stakes and 31 added.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $9.31M. The largest seller was Frazier Management, exiting entirely with an estimated $17.3M sold.

  • 89 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2022, down from 97 in Q4 2021.
  • Funds reported $364M of KalVista Pharmaceuticals stock for Q1 2022, up 16% quarter-over-quarter.
  • 11 funds opened new KalVista Pharmaceuticals positions in Q1 2022 and 19 closed out, a net change of -8 holders.
  • The largest KalVista Pharmaceuticals buyer in Q1 2022 was Tang Capital Management, an estimated $9.31M added.
  • The largest KalVista Pharmaceuticals seller in Q1 2022 was Frazier Management, an estimated $17.3M sold.

Based on aggregated 13F filings for Q1 2022.